Review Article
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
Table 1
Key recommendations on pharmacological treatment of IPF according to current guideline.
| | 2015 guideline | 2011 guideline |
| Therapeutic agent | | | Pirfenidone | Conditional recommendation for use | Weak recommendation against use | Nintedanib | Conditional recommendation for use | Not addressed | Antiacid therapy | Conditional recommendation for use | Weak recommendation for use | Phosphodiesterase-5 inhibitor (sildenafil) | Conditional recommendation against use | Not addressed | Dual endothelin receptor antagonists (bosentan, macitentan) | Conditional recommendation against use | Strong recommendation against use | N-acetylcysteine (NAC) | Conditional recommendation against use | Weak recommendation against use | Azathioprine + corticosteroids + NAC | Strong recommendation against use | Weak recommendation against use | Warfarin | Strong recommendation against use | Weak recommendation against use | Imatinib | Strong recommendation against use | Not addressed | Selective endothelin receptor antagonist (ambrisentan) | Strong recommendation against use | Not addressed |
|
|
Conditional recommendations are synonymous with weak recommendations.
|